Fate Therapeutics, Inc. FATE
2.35
0.02
0.86%
as of 25 Sep
- Market cap
- $279.2M
- P/E
- 0.0×
Follow FATE
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (60.75%) | (55.50%) | (51.84%) | (52.35%) |
+8 more TTM periods Free account |
|
| (39.89%) | (38.01%) | (35.89%) | (37.23%) | ||
ROIC |
0.00% | (1,783.83%) | (2,617.38%) | (585.78%) | |
Return on Tangible Assets |
(71.22%) | (63.96%) | (59.38%) | (61.79%) | |
Average Days of Receivables |
39.53 | 40.68 | 50.31 | 34.88 | |
Free Cash Flow per Share |
(0.88) | (0.90) | (0.94) | (0.97) | |
Free Cash Flow |
(105.42) | (107.73) | (111.67) | (115.30) | |
Capital Expenditures |
(3.47) | (4.63) | (5.59) | (4.73) | |
Piotroski F-Score |
2.00 | 1.00 | 2.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(33.18%) | (29.08%) | (25.82%) | (24.60%) | |
Accounts Receivable Turnover |
6.19 | 4.06 | 2.98 | 2.97 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,546.03% | 1,637.05% | 1,622.46% | 1,625.51% | |
Selling, General and Administrative Expense of Revenue |
612.05% | 670.42% | 699.98% | 716.24% | |
Share Based Compensation of Revenue |
274.78% | 339.96% | 375.02% | 399.55% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.81 | 0.79 | 0.78 | 0.71 | |
Depreciation/Fixed assets |
0.17 | 0.17 | 0.16 | 0.17 | |
Capex/Depreciation |
(0.40) | (0.50) | (0.60) | (0.46) | |
Revenue per Share |
0.05 | 0.05 | 0.06 | 0.06 | |
Operating CF per Share |
(0.85) | (0.86) | (0.89) | (0.93) | |
Capex per Share |
(0.03) | (0.04) | (0.05) | (0.04) | |
Capex to Sales |
0.54 | 0.73 | 0.84 | 0.66 | |
Net Profit Margin |
(1,941.09%) | (2,056.79%) | (2,051.08%) | (2,187.11%) |
Columns are period end dates